Hostname: page-component-8448b6f56d-xtgtn Total loading time: 0 Render date: 2024-04-19T15:08:34.442Z Has data issue: false hasContentIssue false
  • English
  • Français

Botulinum toxin A injection into corrugator muscle for frontally localised chronic daily headache or chronic tension-type headache

Published online by Cambridge University Press:  30 June 2008

J A de Ru  and
J Buwalda
J A de Ru*
Affiliation:
Department of Otorhinolaryngology - Head Neck Surgery, University Medical Center Utrecht, The Netherlands
J Buwalda
Affiliation:
Department of Otorhinolaryngology - Head Neck Surgery, University Medical Center Utrecht, The Netherlands
*
Address for correspondence: Dr J A de Ru, ENT Surgeon, Department of Otolaryngology-Head Neck Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Fax: 0031 302541922 E-mail: j.a.deru@kmb.azu.nl
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To describe our results with botulinum toxin type A injection for headache in carefully selected patients, and to present the rationale behind this therapy.

Setting:

Tertiary referral centre.

Patients and methods:

This article describes a case series of 10 consecutive patients with frontally localised headache, whose pain worsened when pressure was applied at the orbital rim near the supratrochlear nerve. The patients received a local anaesthetic nerve block with Xylocaine 2 per cent at this site. If this reduced the pain, they were then offered treatment with botulinum toxin.

Intervention:

Injection with 12.5 IU of botulinum toxin A into the corrugator supercilii muscle on both sides (a total of 25 IU).

Main outcome measure:

Pain severity scoring by the patients, ranging from zero (no pain) to 10 (severe pain) on a verbal scale.

Results:

Following injection, all patients had less pain for approximately two months. This treatment did not appear to have lasting side effects.

Conclusion:

Xylocaine injection is a good predictor of the effectiveness of botulinum toxin injection into the corrugator muscle as treatment of frontally localised headache. We hypothesise that this pain is caused by entrapment of the supratrochlearis nerve in the corrugator muscle. Furthermore, we found botulinum toxin injection to be a safe and effective means of achieving pain relief in this patient group.

Keywords

Facial PainSupratrochlear NerveBotulinum Toxin
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 123 , Issue 4 , April 2009 , pp. 412 - 417
Copyright
Copyright © JLO (1984) Limited 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Dodick, DW, Mauskop, A, Elkind, AH, DeGryse, R, Brin, MF, Silberstein, SD. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005;45:315–24CrossRefGoogle Scholar
2 Pakalnis, A, Couch, J. Headache therapy with botulinum toxin: form over substance. Arch Neurol 2008;65:149–51CrossRefGoogle ScholarPubMed
3 Mathew, NT, Frishberg, BM, Gawel, M, Dimitrova, R, Gibson, J, Turkel, C. Botulinum toxin type A (Botox) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005;45:293–307CrossRefGoogle ScholarPubMed
4 Silberstein, SD, Stark, SR, Lucas, SM, Christie, SN, DeGryse, RE. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005;80:1126–37CrossRefGoogle ScholarPubMed
5 Schwartz, BS, Stewart, WF, Simon, D, Lipton, RB. Epidemiology of tension-type headache. JAMA 1998;279:381–3CrossRefGoogle ScholarPubMed
6 Padberg, M, De Bruijn, SFTM, De Haan, RJ, Tavy, DLJ. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 2004;24:675–80CrossRefGoogle ScholarPubMed
7 Rollnik, JD, Tanneberger, O, Schubert, M, Schneider, U, Dengler, R. Treatment of tension-type headache with botulinum toxin type A: a double blind, placebo-controlled study. Headache 2000;40:300–5CrossRefGoogle ScholarPubMed
8 Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004;24(suppl 1):9–160Google Scholar
9 Binder, WJ, Brin, MF, Blitzer, A, Schoenrock, LD, Pogoda, JM. Botulinum toxin type A (Botox) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000;123:669–76CrossRefGoogle ScholarPubMed
10 Barrientos, N, Chana, P. Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. J Headache Pain 2003;4:146–51CrossRefGoogle Scholar
11 Schulte-Mattler, WJ, Krack, P. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double blind, placebo-controlled multicenter study. Pain 2004;109:110–4CrossRefGoogle ScholarPubMed
12 Eross, EJ, Gladstone, JP, Lewis, S, Rogers, R, Dodick, DW. Duration of migraine is a predictor for response to botulinum toxin type A. Headache 2005;45:308–14CrossRefGoogle ScholarPubMed
13 Ashkenazi, A, Silberstein, SD. Botulinum toxin and other new approaches to migraine therapy. Ann Rev Med 2004;55:505–8CrossRefGoogle ScholarPubMed
14 Ashkenazi, A, Silberstein, S. Botulinum toxin type A for the treatment of headache: why we say yes. Arch Neurol 2008;65:146–9CrossRefGoogle ScholarPubMed
15 Roach, ES. Questioning botulinum toxin for headache: reality or illusion. Arch Neurol 2008;65:151–2CrossRefGoogle ScholarPubMed
16 Dirnberger, F, Becker, K. Surgical treatment of migraine headaches by corrugator muscle resection. Plast Reconstr Surg 2004;114:652–7CrossRefGoogle ScholarPubMed
17 Bearden, WH, Anderson, RL. Corrugator superciliaris muscle excision for tension and migraine headaches. Ophthal Plast Reconstr Surg 2005;21:418–22CrossRefGoogle ScholarPubMed
18 Guyuron, B, Kriegler, JS, Davis, J, Amini, SB. Comprehensive surgical treatment of migraine headaches. Plast Reconstr Surg 2005;115:1–9CrossRefGoogle ScholarPubMed
19 Guyuron, B, Varghai, A, Michelow, BJ, Thomas, T, Davis, J. Corrugator supercilii muscle resection and migraine headaches. Plast Reconstr Surg 2000;106:429–34CrossRefGoogle ScholarPubMed
20 Guyuron, B, Tucker, T, Davis, J. Surgical treatment of migraine headaches. Plast Reconstr Surg 2002;109:2183–9CrossRefGoogle ScholarPubMed
21 Schwedt, TJ, Hentz, JG, Dodick, DW. Factors associated with the prophylactic effect of placebo injections in subjects enrolled in a study of botulinum for migraine. Cephalalgia 2007;27:528–34CrossRefGoogle Scholar
22 Evers, S, Olesen, J. Reply: letters to the editor. Cephalalgia 2007;27:468CrossRefGoogle Scholar
23 Schmitt, WJ, Slowey, E, Fravi, N, Weber, S, Burgunder, J-M. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache 2001;41:658–64CrossRefGoogle ScholarPubMed
24 Behmand, RA, Tucker, T, Guyuron, B. Single-site botulinum toxin type A injection for elimination of migraine trigger points. Headache 2003;43:1085–9CrossRefGoogle ScholarPubMed
25 Smuts, JA, Schultz, D, Barnard, A. Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. Headache 2004;44:801–5CrossRefGoogle ScholarPubMed
26 Mosser, S, Guyuron, B, Janis, J, Rohrich, R. The anatomy of the greater occipital nerve: implications for the etiology of migraine headaches. Plast Reconstr Surg 2004;113:693–7CrossRefGoogle ScholarPubMed
27 Fernández de las Peñas, C, Cuadrado, ML, Arendt Nielsen, L, Simons, DG, Pareja, JA. Myofascial trigger points and sensitization: an updated pain model for tension-type headache. Cephalalgia 2007;27:383–93CrossRefGoogle ScholarPubMed
28 Bendtsen, L. Central sensitization in tension-type headache: possible patho-physiological mechanisms. Cephalalgia 2000;29:486–50CrossRefGoogle Scholar
29 McPartland, JM, Simons, DG. Myofascial trigger points: translating molecular theory into manual therapy. J Man Manipul Therapy 2006;14:232–9CrossRefGoogle Scholar
30 Ho, K-Y, Tan, K-H. Botulinum toxin A for myofascial trigger point injection: a qualitative systematic review. Eur J Pain 2007;11:519–27CrossRefGoogle ScholarPubMed
31 Muehlberger, T, Fisher, P, Lehnhardt, M. The anatomy of the surgical treatment of migraine [in German]. Zentralbl Chir 2005;130:288–92CrossRefGoogle ScholarPubMed
32 Dutton, JJ, Fowler, AM. Botulinum toxin in ophthalmology. Surv Ophthalmol 2007;52:13–31CrossRefGoogle ScholarPubMed